Middle East Conflict Puts Cancer Drug Supply at Risk as Pharma Scrambles to Reroute Cold-Chain Medicines

March 17, 2026

The escalating conflict in the Middle East has moved beyond a regional security crisis, now threatening the global “cold-chain” lifeline that delivers refrigerated oncology treatments to thousands of patients. As major air cargo corridors face unprecedented disruptions, pharmaceutical giants and logistics experts warn that life-saving cancer drugs—which require strict temperature controls and have short shelf lives—are at the highest risk of supply shortages. With key transit hubs constrained, the industry is now in a race against time to reroute shipments before hospital inventories run dry.

The Logistics of Life: Why Air Corridors Matter

The current geopolitical instability, marked by restricted airspaces and safety concerns over traditional flight paths, has struck at the heart of the global pharmaceutical supply chain. Airports in Dubai, Abu Dhabi, and Doha serve as the world’s primary “super-hubs,” connecting manufacturers in Europe and North America to patients across the Gulf, Asia, and parts of Africa.

According to industry logistics data, more than 20% of global air cargo—including vaccines and critical biologics—is exposed to disruption when Middle Eastern corridors are compromised. Unlike standard cargo, high-value medicines are almost exclusively transported via air freight to ensure they reach their destination quickly.

“Air freight is the only viable option for short-shelf-life drugs,” explains Wouter Dewulf, a professor of transport and logistics at Antwerp Management School. “When you force these flights to take longer, circuitous routes, you aren’t just increasing fuel costs; you are increasing the window of risk for ‘temperature excursions’—where a drug becomes too warm or accidentally freezes, rendering it medically useless.”

Why Oncology Patients Face the Greatest Risk

While many medications can sit in a warehouse for years, modern cancer therapies are notoriously fragile. Specifically, monoclonal antibodies and other biologic therapies must be maintained at a constant temperature of 2°C to 8°C (35.6°F to 46.4°F).

Industry executives and supply-chain specialists identify oncology products as being at the “highest risk” for several reasons:

• Shelf Life: Many released oncology batches are valid for only a few months.

• Dosing Sensitivity: Cancer treatment relies on strict cycles. A delay of even one week can allow a tumor to progress or force a patient to restart a grueling induction phase.

• Logistics Complexity: These drugs often require specialized thermal packaging and real-time GPS temperature monitoring.

Reports from the field suggest that some healthcare providers in the Gulf region have warned they could face stock-outs within four to six weeks if current transit delays—which can add days to a journey—are not mitigated.

The Industry “War Room” Response

In response to the crisis, pharmaceutical manufacturers and specialized logistics firms like Marken have activated 24/7 “war rooms.” The goal is to map every shipment in transit and pivot to alternative hubs such as Jeddah, Riyadh, Istanbul, or even Singapore.

Doaa Fathallah, Chief Operating Officer at Marken, noted that teams are engaged in round-the-clock rerouting as airspace restrictions shift “almost daily.” To preserve the “cold chain” during these longer journeys, companies are:

1. Enhancing Packaging: Increasing the use of dry ice and advanced vacuum-insulated panels.

2. Prioritizing Cargo: Implementing “patient-critical” labels to ensure cancer drugs are the first moved onto available flights.

3. Multimodal Workarounds: Flying medicines to stable regional airports and then using refrigerated trucks for the final leg of the journey—a process that is safer but significantly slower.

Comparison of Transit Risks

Expert Perspectives: A Fragile System

The World Health Organization (WHO) has previously noted that the cancer drug supply chain was fragile even before the current conflict, due to post-pandemic manufacturing hiccups. This new disruption acts as a “stress test” on an already weakened system.

Medical professionals not involved in the logistics side are watching the situation with concern. Dr. Sarah Jenkins, an oncology consultant (fictionalized for context), notes: “We tell our patients that consistency is everything. If the supply chain breaks, it’s not just a logistical failure; it’s a clinical one. We may have to look at ‘therapeutic substitution’—switching to a different, more available drug—which is never ideal mid-treatment.”

Practical Advice for Patients and Families

For patients currently undergoing treatment in affected regions, experts emphasize preparation over panic.

• Communication: Maintain daily contact with your oncology clinic. They will have the most up-to-date information on their specific inventory.

• Documentation: Keep a physical copy of your treatment plan, including exact dosages and brand names.

• Avoid Stockpiling: While it is tempting to try to “buy ahead,” many of these drugs require professional refrigeration. Storing them in a home fridge can lead to accidental spoilage, wasting life-saving medicine that someone else may need.

Limitations and Counterarguments

While the situation is serious, there are reasons for cautious optimism. Most major pharmaceutical companies maintain three months of safety stock within local markets to buffer against exactly this type of short-term geopolitical shock. Furthermore, many logistics providers argue that the industry has become significantly more resilient since the COVID-19 pandemic, with better tracking technology and more diverse routing options than a decade ago.

The “four-to-six-week” shortage window is a projection, not a certainty. If diplomatic efforts stabilize air corridors or if alternative hubs scale up quickly, the impact on patients may remain minimal.

The Path Forward

This crisis underscores a growing call from international health agencies for “geographic diversification.” Relying on a handful of Middle Eastern hubs for one-fifth of the world’s medicine creates a single point of failure. Moving forward, health authorities may push for more localized “fill-finish” manufacturing sites to ensure that even if the planes stop flying, the medicine keeps flowing.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

Study and Industry Citations:

• Reuters (via The Print). (2026, March 16). “Analysis – Middle East war disrupts pharma air routes, risks cancer drugs supply.”

• The Economic Times. (2026, March 16). “Middle East war disrupts pharma air routes, risks cancer drugs supply.”